— Join our monthly newsletter

Category: Real world platform

Synergistic effect of Tafasitamab and Lenalidomide highlighted by an RWE Study

An observational retrospective study has evaluated the combination of tafasitamab (MOR208) with lenalidomide (Revlimid) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who were not eligible for high-dose chemotherapy and stem cell transplant.

Read More

Tech Giants’ Healthcare drive

Due to the enormous knowledge and expertise gained in the analysis and usage of big data driving digital innovation, it appears that the tech giants will be making a crucial impact in this sector.

Read More

FDA on Real-World Data quality issues: an early guide

Considering the growing interest supported by the improvement of technologies in this sector, the agency is currently investigating when the use of observational data “may be appropriate for evaluating effectiveness from a broad policy perspective and also how individual drug manufacturers submit proposals for using real world data to support marketing applications”.

Read More

RWE studies: an opportunity your company should not miss

Until now, companies have considered RWE studies useful mostly for post-approval safety; there are some big opportunities on the Real-World Evidence horizon that industry and regulators will be considering and implementing soon.

Read More

What is the future of AI and drug development?

A review recently published in the Journal Trends in Pharmacological Sciences analyzed the potential improvements that AI could bring to drug development in the next decade

Read More

Bring Your Own Device

Launched by Fitbit, Bring Your Own Device is the first digital health technology initiative. It is part of the National Institutes of Health’s All of Us research program and it is developed under the Precision Medicine Initiative. It consists in a fitness tracker that has the goal to collect data from a variety of populations drawing on surveys, physical measurements, EHRs, and digital health technologies.

Read More

The new pacemaker (evidence) generation

It’s been 60 years since the first implantable pacemaker was introduced into the market. Today a new monitoring process is available for patients and Hp’s: Medtronic – whose founder created some of the first pacemaker models – has designed a mobile app that enables pacemakers-communication via mobile phone or tablets.

Read More

MyStudies App, the FDA’S real-world lens

FDA has recently taken action in the real-world evidence field by releasing a new health App: MyStudies App is a standardized digital platform where researchers can collect, organize and analyze a variety of data directly from the real-world environment.

Read More